VivoSeq
Other

Targeted Therapy

0

Pipeline Programs↗

14

Active Trials↗

1

Companies Involved↗

Targeted Therapy is an early-stage landscape with 0 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

57/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Recruiting7 · 28%
Not yet recruiting6 · 24%
Unknown status4 · 16%
Completed4 · 16%
Withdrawn2 · 8%
Terminated1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

25 trials

Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT03321045·10 enrolled
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy
Recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT06130787·321 enrolled
Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation
Recruiting·NNational Taiwan University Hospital·Phase 2·NCT06632834·230 enrolled
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
Recruiting·LLeiden University Medical Center·Phase 2·NCT06079333·20 enrolled
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Recruiting·RRuijin Hospital·Phase 2·NCT06793189·145 enrolled
Korean College of Rheumatology Biologics and Targeted Therapy Registry
Recruiting·SSeoul National University Hospital·N/A·NCT01965132·10,000 enrolled
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Recruiting·Novartis logoNovartis·Phase 2/3·NCT06780670·443 enrolled
Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03235245·271 enrolled
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Not yet recruiting·VVanderbilt-Ingram Cancer Center·Phase 1·NCT06828588·30 enrolled
Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)
Not yet recruiting·UUniversity Hospital, Lille·Phase 2·NCT06734884·96 enrolled
Dynamic CtDNA-guided Targeted Therapy in DLBCL
Not yet recruiting·RRuijin Hospital·Phase 2·NCT06748521·108 enrolled
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
Not yet recruiting·Cchenxu·Phase 2·NCT07474064·146 enrolled
FLT3-ITD Targeted Therapy in Fit AML Patients
Not yet recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2/3·NCT07425808·230 enrolled
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
Not yet recruiting·—·Phase 2·NCT07381309·114 enrolled
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
Completed·IiOMEDICO AG·Phase 4·NCT01266837·64 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)